drugset / Trial / NCT00692341

Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics

NCT00692341

Phase 1 Completed 24 enrolled Pfizer
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the effects of mild and moderate impairment of hepatic function on the single-dose pharmacokinetics, safety and tolerability of AG-013736.

Timeline

Start
2008-05
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule 5 mg Oral

Indications